Navigation Links
Memory Pharmaceuticals Provides Update on NASDAQ Listing Status
Date:10/28/2008

our website at http://www.memorypharma.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or Memory Pharmaceuticals' prospects, future financial position, future revenues and projected costs should be considered forward-looking. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, including the outcome of clinical trials of Memory Pharmaceuticals' drug candidates and whether they demonstrate these candidates' safety and effectiveness; the risks and uncertainties associated with: obtaining additional financing to support Memory Pharmaceuticals' R&D and clinical activities and operations; obtaining regulatory approvals to conduct clinical trials and to commercialize Memory Pharmaceuticals' drug candidates; Memory Pharmaceuticals' ability to enter into and maintain collaborations with third parties for its drug development programs; Memory Pharmaceuticals' dependence on its collaborations and its license relationships; achieving milestones under Memory Pharmaceuticals' collaborations; Memory Pharmaceuticals' dependence on preclinical and clinical investigators, preclinical and clinical research organizations, manufacturers and consultants; protecting the intellectual property developed by or licensed to Memory Pharmaceuticals; and Memory Pharmaceuticals' ability to maintain listing on the Nasdaq Capital Market. These and other risks are described in greater detail in Memory Pharmaceuticals' filings with the Securities and Exchange Commission. Memory Pharmaceuticals may not actually achieve the goals or plans described in its forward-looking statements, and
'/>"/>

SOURCE Memory Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Memoirs of a qubit: Hybrid memory solves key problem for quantum computing
2. Blanchette Rockefeller Neurosciences Institute Hosts First-Ever International Forum on Memory and Memory Disorders and Dedicates New $30 Million Research Facility
3. Jellyfish Protein Shows Potential to Help With Memory
4. Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908
5. SAFC Hitech(TM) Successfully Demonstrates Device-Quality GST Precursors For Phase Change Memory Applications
6. Memory Pharmaceuticals Closes Final Tranche of Equity Financing with The Stanley Medical Research Institute
7. Memory Pharmaceuticals to Announce Second Quarter 2008 Results on Wednesday, August 13, 2008
8. New kind of MRI enables study of magnets for computer memory
9. Memory Pharmaceuticals Receives Anticipated NASDAQ Staff Determination Letter
10. Memory Pharmaceuticals Reports First Quarter 2008 Financial Results
11. Memory Pharmaceuticals to Announce First Quarter 2008 Results on Wednesday, May 14, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... PA (PRWEB) August 29, 2014 Pittcon ... Hub MacDonald, and colleague Koichiro Matsuda, Horiba Scientific, have ... on September 5, 2014. JASIS , Asia’s largest ... 3-5, 2014, in Makuhari Messe, Japan. , The ... Tools for Bioanalysis from Single Molecules to Single Cells” ...
(Date:8/29/2014)... 2014 Local veterinarian, Dr. Keith Clement, ... seeking candidates to participate in an investigational study of ... ultimate goal of this study is to determine if ... or two arthritically affected joints can help reduce pain ... for the current investigational study must be older than ...
(Date:8/29/2014)... Due to a misstatement posted by the ... Stem Cell Technology Center, LLC ( ASCTC ) was reported ... research that might benefit ALS patients. Because of ASCTC's ... cell technologies and therapeutic applications, FRC listed ASCTC as one ... donors who wish not to support research that requires the ...
(Date:8/29/2014)... San Antonio, TX (PRWEB) August 29, 2014 ... 9001:2008 and ISO 13485:2003 certified, GAMP® 5 compliant ... been awarded an international Phase II clinical trial ... non-Hodgkin’s lymphoma. , Throughout this trial, Intrinsic Imaging ... but not limited to, protocol and charter development, ...
Breaking Biology Technology:Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2
... on November 2nd and New York on November ... Inc. (Nasdaq:,FVRL), a biopharmaceutical company developing patient-specific, active,immunotherapies ... the,Company will present at three upcoming investor conferences: ... Ghalie, M.D., Chief Medical Officer, will present at ...
... (Nasdaq:,SIAL), a life science company dedicated to providing ... and Oxford,BioMedica (LSE: OXB), a leading gene therapy ... confirming the strength and validity of,intellectual property owned ... field to Sigma-Aldrich. The ruling was part of ...
... to "de-cloak" cancers -, TORONTO, Oct. 25 ... company discovering and developing the next wave of,antibody ... from its Trop-2 and CD59 antibody programs. ARIUS ... at the AACR press,conference today at 9:30 a.m. ...
Cached Biology Technology:Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference 2Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute 2Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute 3Arius announces new findings in Trop-2 and CD59 CANCER antibody programs 2Arius announces new findings in Trop-2 and CD59 CANCER antibody programs 3
(Date:9/1/2014)... nucleotidethe basic building block of DNAcould initiate fragile X syndrome, the ... The Journal of Cell Biology . ... gene on the X chromosome called fragile X mental retardation ... 360 men carry a so-called premutation, in which a series of ... is slightly longer than normal. These repeats are prone to even ...
(Date:9/1/2014)... As nocturnal animals, bats are perfectly adapted to a life ... between the reflected echoes to measure distance to obstacles or ... different echo delays. A study carried out by researchers at ... that this map dynamically adapts to external factors. , ... bat flies in too close to an object, the number ...
(Date:8/31/2014)... Scientists at the University of Warwick have discovered that ... , The substance, methylglyoxal - MG, was found ... of bad cholesterol from the body. , Low ... to heart disease, with increased levels of MG being ... kidney problems. , Supported by funding from the ...
Breaking Biology News(10 mins):A nucleotide change could initiate fragile X syndrome 2Zooming in for a safe flight 2Sugar substance 'kills' good HDL cholesterol, new research finds 2
... carried through the atmosphere before settling on the ocean ... new research from the University of Michigan and the ... Earth Science and Technology (SOEST) combines biogeochemistry and direct ... cycle is colliding with ocean fishand the human seafood ...
... members from The University of Texas at Arlington are ... of Texas System Board of Regents for excellence in ... $25,000 cash award and recognize faculty members at UT ... innovation at the undergraduate level. The professors were recognized ...
... Center Researcher Song-Yi Park, PhD, along with her colleagues, ... vegetables may lower the risk of invasive bladder cancer ... part of the Multiethnic Cohort (MEC) Study, established in ... factors, and cancer risk. Park and her fellow researcher,s ...
Cached Biology News:Ocean fish acquire more mercury at depth 2Ocean fish acquire more mercury at depth 3Ocean fish acquire more mercury at depth 49 UT Arlington educators honored for teaching excellence 2
IC50: 3 ng/ml · Limit of detection: 0.9 ng/ml...
Request Info...
Request Info...
... siRNA service provides the premium quality siRNAs ... Custom siRNAs can be readily ordered online ... sequence, or by providing the sense and ... Silencer Validated and Silencer Pre-designed siRNAs, which ...
Biology Products: